Pathway Capital Management LP Purchases Shares of 69,450 Denali Therapeutics Inc. (NASDAQ:DNLI)

Pathway Capital Management LP purchased a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 69,450 shares of the company's stock, valued at approximately $1,490,000. Denali Therapeutics makes up 1.7% of Pathway Capital Management LP's investment portfolio, making the stock its 10th largest holding. Pathway Capital Management LP owned 0.05% of Denali Therapeutics at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of DNLI. Victory Capital Management Inc. grew its position in shares of Denali Therapeutics by 5.5% during the 3rd quarter. Victory Capital Management Inc. now owns 12,081 shares of the company's stock worth $249,000 after buying an additional 630 shares during the period. Amalgamated Bank raised its position in shares of Denali Therapeutics by 3.9% during the 3rd quarter. Amalgamated Bank now owns 18,255 shares of the company's stock valued at $377,000 after acquiring an additional 679 shares during the last quarter. Assetmark Inc. lifted its stake in shares of Denali Therapeutics by 49.1% in the 3rd quarter. Assetmark Inc. now owns 2,148 shares of the company's stock valued at $44,000 after purchasing an additional 707 shares during the period. Alps Advisors Inc. boosted its position in shares of Denali Therapeutics by 0.8% in the 3rd quarter. Alps Advisors Inc. now owns 101,400 shares of the company's stock worth $2,092,000 after purchasing an additional 780 shares during the last quarter. Finally, Los Angeles Capital Management LLC boosted its position in shares of Denali Therapeutics by 2.3% in the 3rd quarter. Los Angeles Capital Management LLC now owns 46,002 shares of the company's stock worth $949,000 after purchasing an additional 1,046 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on DNLI. Wedbush cut their target price on Denali Therapeutics from $31.00 to $30.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 8th. The Goldman Sachs Group reduced their target price on Denali Therapeutics from $73.00 to $50.00 and set a "buy" rating on the stock in a report on Thursday, February 29th. Stifel Nicolaus lowered their price objective on shares of Denali Therapeutics from $26.00 to $22.00 and set a "hold" rating for the company in a research report on Wednesday, May 8th. UBS Group cut their target price on Denali Therapeutics from $70.00 to $32.00 and set a "buy" rating on the stock in a research note on Tuesday, April 9th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $95.00 price target on shares of Denali Therapeutics in a research report on Wednesday, May 8th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, Denali Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $40.22.

Denali Therapeutics Stock Up 1.3 %

Shares of NASDAQ DNLI traded up $0.27 during trading hours on Friday, hitting $20.51. The company had a trading volume of 750,216 shares, compared to its average volume of 1,203,576. The stock has a market capitalization of $2.92 billion, a P/E ratio of -21.36 and a beta of 1.39. Denali Therapeutics Inc. has a 1-year low of $14.56 and a 1-year high of $33.31. The firm's 50 day moving average is $18.67 and its 200-day moving average is $18.87.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.01. Denali Therapeutics had a negative net margin of 36.51% and a negative return on equity of 11.46%. During the same period in the prior year, the firm posted ($0.80) earnings per share. On average, sell-side analysts predict that Denali Therapeutics Inc. will post -2.77 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Vicki L. Sato sold 1,666 shares of the company's stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $18.29, for a total value of $30,471.14. Following the transaction, the director now owns 118,043 shares in the company, valued at approximately $2,159,006.47. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, Director Steve E. Krognes sold 92,500 shares of the firm's stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $20.50, for a total transaction of $1,896,250.00. Following the transaction, the director now directly owns 47,341 shares of the company's stock, valued at $970,490.50. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Vicki L. Sato sold 1,666 shares of the business's stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $18.29, for a total transaction of $30,471.14. Following the completion of the sale, the director now directly owns 118,043 shares of the company's stock, valued at approximately $2,159,006.47. The disclosure for this sale can be found here. 7.90% of the stock is currently owned by corporate insiders.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.